RNAC
Cartesian Therapeutics Inc.
7.90$
-1.1%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 86.0% | 90.9% | 97.2% | 97.6% | 94.6% | 97.1% | 91.5% | 90.3% | 89.3% | 29.7% | 49.8% | 43.6% | |
| 74.6% | 75.5% | 65.7% | 69.9% | 84.1% | 90.6% | 83.8% | 71.3% | 64.2% | 25.2% | 48.9% | 42.2% | |
| 74.6% | 85.1% | 94.2% | 95.6% | 84.1% | 90.6% | 83.8% | 80.1% | 81.1% | 25.2% | 48.9% | 42.2% | |
| 3.0% | 1.9% | 0.2% | 0.1% | – | 5.0% | 4.4% | 6.2% | 5.9% | 2.9% | 0.2% | 0.4% | |
| – | – | 0.0% | -2.0% | – | – | 0.6% | – | – | – | – | – | |
| 8.9% | 4.7% | 2.3% | 2.1% | 4.8% | 1.5% | 0.8% | 1.3% | 1.7% | – | – | – | |
| – | – | 0.0% | 0.0% | – | – | – | – | 0.0% | 15.8% | 11.1% | 16.2% | |
| – | – | 0.0% | 0.0% | – | – | – | – | – | 49.4% | 34.6% | 31.7% | |
| 494.8% | 372.0% | 38.5% | 48.7% | 112.2% | 91.6% | 110.9% | 85.9% | 43.4% | 244.3% | 101.6% | 142.6% | |
| 41.5% | 17.0% | 15.3% | 10.9% | 79.0% | 35.1% | 49.3% | 45.2% | 15.1% | 22.4% | 5.3% | 5.0% | |
| 11.6% | 7.9% | 4.6% | 0.0% | 48.1% | 19.4% | 0.5% | 4.4% | 6.1% | 0.7% | 0.7% | 1.4% | |
| 1.6% | 5.1% | 4.3% | 1.6% | 2.5% | 0.5% | 0.3% | 0.1% | 0.2% | 1.0% | 0.1% | 0.4% | |
| 21.7% | 27.7% | 8.9% | 20.8% | 0.0% | – | 15.0% | 12.3% | 10.7% | – | – | – | |
| -394.8% | -272.0% | 61.5% | 51.3% | -12.2% | 8.4% | -10.9% | 14.1% | 56.6% | -144.3% | -1.6% | -42.6% | |
| -377.4% | -260.4% | -169.7% | -214.5% | -630.4% | -337.2% | -244.6% | -269.1% | -238.1% | -201.5% | -159.1% | -277.4% | |
| 1.6% | 30.0% | 0.3% | 0.6% | 1.4% | 1.3% | 1.7% | 2.0% | 2.4% | 1.7% | 5.4% | 8.8% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.